Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 18/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | PFKP | Q01813 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.43 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738648 | 0.82 | ATR (0.47) | MTORPIK3CAATRPIK3CD | |
| SCHEMBL2487867 | 0.82 | ATR (0.47) | MTORPIK3CAATRPIK3CD | |
| SCHEMBL20742089 | 0.82 | MTOR (0.48) | MTORPIK3CAATRPIK3CD | |
| SCHEMBL24269976 | 0.82 | ATR (0.47) | MTORPIK3CAATRPIK3CDPIK3C3 | |
| SCHEMBL20742087 | 0.82 | MTOR (0.48) | MTORPIK3CAATRPIK3CD | |
| SCHEMBL24269977 | 0.82 | ATR (0.47) | MTORPIK3CAATRPIK3CDPIK3C3 | |
| SCHEMBL2492704 | 0.82 | ATR (0.47) | MTORPIK3CAATRPIK3CD | |
| SCHEMBL2370376 | 0.82 | MTOR (0.55) | MTORPIK3CAATRPIK3R1 | |
| SCHEMBL2370380 | 0.82 | MTOR (0.55) | MTORPIK3CAATRPIK3R1 | |
| SCHEMBL11926409 | 0.80 | ALDH1A1 (0.49) | MTORPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3235816-B1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN) | 2020-02-12 | — | — | EP | disclosed |
| US-10227324-B2 | 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-03-12 | — | — | US | disclosed |
| US-10227324-B2 | 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-03-12 | — | — | US | disclosed |
| US-20170349568-A1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-12-07 | — | — | US | disclosed |
| US-20170349568-A1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-12-07 | — | — | US | disclosed |
| US-20170349568-A1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-12-07 | — | — | US | disclosed |
| EP-3235816-A1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016095833-A1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海海雁医药科技有限公司 | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349568-A1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | PIK3CA, PIK3CD, PIK3CG | MTOR 14/4885PIK3CA 1/4885ATR 1151/4885 |
| US-10227324-B2 | 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof | PIK3CA, PIK3CD, PIK3CG | MTOR 14/4885PIK3CA 1/4885ATR 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.